CDKN2A Mutation: Friend or Foe in Esophageal Cancer?

In a groundbreaking study published in Nature Cancer, researchers from the Queen Mary University of London have discovered that a genetic mutation in the CDKN2A gene, long considered a driver of esophageal cancer, may also play a protective role in the early stages of the disease. This dual nature challenges traditional views on cancer genetics and offers insights into better predicting cancer risk and outcomes.

Esophageal adenocarcinoma, a subtype of esophageal cancer, often develops from a condition known as Barrett’s esophagus, where esophageal lining cells become abnormal. While only about 1% of people with Barrett’s esophagus progress to cancer each year, the reasons behind this variation remain unclear.

Researchers analyzed genomic data from over 1,000 patients with esophageal adenocarcinoma and 350 individuals with Barrett’s esophagus. Surprisingly, they found that CDKN2A mutations were more common in patients with Barrett’s esophagus who never developed cancer.

The study revealed a fascinating interplay between CDKN2A and p53, another key tumor suppressor gene often called the ‘guardian of the genome.’ In the early stages, loss of CDKN2A may help prevent the damaging effects of losing p53, reducing the likelihood of progression to cancer. However, in advanced stages, CDKN2A loss accelerates tumor aggression and worsens outcomes.

Lead researcher Professor Francesca Ciccarelli likened the dual nature of CDKN2A to Janus, the Roman god of transitions, symbolizing a mutation that can be both protective and harmful depending on the stage of the disease.

This discovery has profound implications for assessing cancer risk in patients with Barrett’s esophagus. For instance, patients with an early CDKN2A mutation but no p53 mutations may face a lower risk of cancer progression, while the presence of CDKN2A mutations in later stages might signal poor prognosis.

Experts believe these findings could lead to personalized cancer prevention and treatment strategies, focusing on the timing and combination of mutations rather than viewing them as inherently ‘good’ or ‘bad.’

This study highlights the importance of precision medicine in understanding and treating complex diseases like esophageal cancer and underscores the need for further research to translate these findings into clinical practice.

More Information: Ganguli, P., et al. (2025) Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer. Nature Cancer. doi.org/10.1038/s43018-024-00876-0.